Table 2. Summary of quantifications of BIC RNA, miR-155, miR-15a, miR-16, and let-7a as determined by Invader assays
|
Sample name |
Type |
Immunohistochem. |
BIC RNA, copies per cell (SD) |
miR-155, copies per cell (SD) |
miR-15a, copies per cell (SD) |
miR-16, copies per cell (SD) |
let-7a, |
|
SUDHL6 |
DLBCL cell line |
GC like |
38 (11) |
570 (120) |
3,000 (490) |
7,300 (450) |
1,100 (68) |
|
OCI-Ly3 |
DLBCL cell line |
ABC like |
990 (84) |
8,100 (230) |
1,100 (52) |
2,500 (170) |
630 (36) |
|
HDLM2 |
Hodgkin cell line |
|
22 (5) |
110 (20) |
1,100 (55) |
2,100 (110) |
1,100 (77) |
|
L428 |
Hodgkin cell line |
|
130 (1) |
4,500 (220) |
670 (47) |
2,600 (220) |
1,200 (150) |
|
KMH2 |
Hodgkin cell line |
|
170 (27) |
5,700 (450) |
380 (86) |
1,800 (220) |
720 (5) |
|
L591 |
Hodgkin cell line |
|
250 (18) |
7,400 (730) |
410 (55) |
1,800 (190) |
910 (97) |
|
L1236 |
Hodgkin cell line |
|
250 (7) |
6,700 (280) |
1,100 (11) |
2,900 (230) |
950 (3) |
|
S4* |
B cell |
|
33 (15) |
51 (130) |
7,700 (350) |
8,600 (190) |
2,300 (43) |
|
S5 |
B cell |
|
56 (6) |
250 (180) |
7,100 (450) |
8,900 (620) |
2,400 (78) |
|
I1 |
DLBCL |
GC |
110 (10) |
2,000 (150) |
1,900 (110) |
4,000 (230) |
2,000 (130) |
|
D10 |
DLBCL |
GC |
99 (8) |
2,100 (36) |
8,500 (140) |
11,300 (190) |
3,300 (170) |
|
I6 |
DLBCL |
ABC |
150 (21) |
2,800 (260) |
3,300 (190) |
5,400 (500) |
3,500 (140) |
|
I2 |
DLBCL |
ABC |
120 (26) |
2,800 (410) |
2,800 (14) |
5,900 (550) |
1,200 (33) |
|
D19 |
DLBCL |
ABC |
220 (20) |
3,600 (140) |
2,200 (57) |
4,500 (180) |
2,000 (170) |
|
D6 |
DLBCL |
ABC |
1,180 (84) |
4,700 (80) |
3,700 (120) |
6,200 (690) |
2,000 (62) |
|
I14 |
DLBCL |
ABC |
470 (31) |
4,900 (260) |
4,900 (260) |
8,000 (330) |
4,500 (240) |
|
I5 |
DLBCL |
ABC |
360 (30) |
5,200 (550) |
4,500 (350) |
5,900 (550) |
1,800 (160) |
|
D18 |
DLBCL |
ABC |
410 (35) |
5,400 (710) |
3,000 (110) |
5,000 (480) |
2,600 (14) |
|
D9 |
DLBCL |
ABC |
440 (28) |
8,500 (370) |
2,900 (32) |
5,900 (220) |
4,000 (420) |
|
D7 |
DLBCL |
ABC |
480 (14) |
10,500 (260) |
4,500 (260) |
8,900 (410) |
3,000 (230) |
|
L23 |
CLL |
|
170 (13) |
3,500 (110) |
5,300 (240) |
7,600 (740) |
3,800 (220) |
|
L22 |
CLL |
|
190 (8) |
4,200 (45) |
3,700 (170) |
7,400 (780) |
2,700 (190) |
|
L25 |
CLL |
|
220 (3) |
6,600 (610) |
4,900 (420) |
9,400 (540) |
4,200 (420) |
|
L27 |
Marginal zone |
|
150 (1) |
5,300 (100) |
1,900 (73) |
7,400 (1,200) |
2,000 (72) |
Expression levels are reported for both cultured cell lines and clinical lymphoma samples (run in triplicate). These data were used for the analyses shown in Figs. 3 and 4. Total RNA samples were prepared from cultured cell lines, lymphocyte fractions (B cells) or frozen tissue. Phenotype classifications for diffuse large B cell lymphoma (DLBCL) cases were performed on formalin-fixed paraffin-embedded tissue. Nonactivated germinal center (GC) cells are positive for BCL-6 and/or CD10, but negative for MUM-1 and CD138; activated B cells (ABC) are positive for MUM-1 and +/– for BCL-6, CD10, and CD138. CLL, chronic lymphocytic leukemia.
*miR-155 was not significantly detected over background in sample S4.